

# Your AAV Suspension Platform


De-risked, streamlined, commercially viable

- **A streamlined platform** using our established and ready-to-use proprietary cell lines and plasmids for AAV production; pre-qualified assays from our library; robust and optimized unit operations; ready to go tech-transfer documentation.
- **A de-risked path to commercialization** with our standardized, systematic approach to tech transfers, manufacturing and pre-approval inspection readiness, leveraging our established global quality and regulatory infrastructure.
- **Commercial viability** using a platform with high AAV productivity through our proprietary cell line and plasmids. Availability of analytics to optimize full vs empty capsids early in process development. Flexible cGMP capacity and operational models to support variable demand.

## Lonza Approach to Successful Commercialization

20+

Years of experience in viral vectors



Available capacity with additional expansion space



2 successful FDA inspections for cell & gene products commercialization




Proprietary components



Significant investments in viral vector technologies and innovation



Dedicated regulatory experts offer phase-appropriate support to secure and speed-up your product's journey to commercialization




Flexible operational model for manufacturing



## Learn More

[Click here](#) to learn more and discuss your AAV development and manufacturing strategy, or email [pharma@lonza.com](mailto:pharma@lonza.com)



## High Performing Production Host Cell Line and Plasmids

At the heart of our robust processes is our AAV Transient Expression platform. Lonza's proprietary 5B8 Host Cell Line and AAV Production Plasmids were developed based on our experience of the needs of developers of gene therapies. The 5B8 cell line is a HEK293 suspension host cell line, selected and developed at Lonza for high AAV productivity. AAV productivity is boosted by combination of Lonza's Helper plasmid and promoter designed to balance

expression of your Rep/Cap proteins across multiple AAV serotypes and genes of interest (GOIs). The 5B8 cell line is cultured in animal-component-free conditions and has demonstrated scalability for AAV production. Established research and cGMP cell banks are available for customer projects. The 5B8 cell line and know-how for production of Lonza's pHelper plasmid and Rep/Cap promoter are available to license for use in your laboratory or production facility.

### Now Available to Take to Your Laboratory

#### 5B8 Production Host Cell Line

- Suspension HEK293 cell line
- High AAV productivity for multiple serotypes and GOIs
- Proven scalability for AAV production
- Research and cGMP cell banks available under license

#### AAV Production Plasmids

- Proprietary know-how on pHelper plasmid and promoter for balanced Rep/Cap expression
- Higher productivity and titers<sup>1</sup>
- Optimized for multiple AAV serotypes and GOIs

<sup>1</sup>Lonza in-house data, comparison to standard commercially available plasmids.

To license our AAV platform components, email [VVET@lonza.com](mailto:VVET@lonza.com)



### Learn More

[Click here](#) to learn more and discuss your AAV development and manufacturing strategy, or email [pharma@lonza.com](mailto:pharma@lonza.com)

The information contained herein is intended for general marketing purposes only. While Lonza makes efforts to include accurate and up-to-date information, it makes no representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided herein and disclaims any liability for the use of this publication and that all access and use of the information contained herein are at their own risk. Lonza may change the content of this publication at any time without notice but does not assume any responsibility to update it. All trademarks belong to Lonza and are registered in Switzerland or to their respective third party owners.